Nazeri Astaneh Ali, Sadighi Gita, Alibeigi Neda, Abdollahzadeh Parisa, Abdollahzadeh Bahareh
Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Med J Islam Repub Iran. 2022 Feb 23;36:13. doi: 10.47176/mjiri.36.13. eCollection 2022.
Identifying treatment-response predictors could help improve treatment protocols as well as appropriately tailoring them to each subject, leading to a more desirable and accelerated recovery in patients. Thus, the present study aimed to investigate the role of demographic characteristics, memory deficits, and executive functioning impairments in failure to respond to fluvoxamine among patients with obsessive-compulsive disorder (OCD). This 2-group design (treatment-responsive and treatment-resistant) experimental study explored 76 participants who had received fluvoxamine monotherapy for OCD for ≥6 months. The study participants were from Iran. Four data collection tools were used in this study (ie, Demographic Data Form, WMS-III, WCST, and Y-BOCS). The achieved data were analyzed in SPSS-16 by descriptive statistics, such as mean and standard deviation and frequency and percentages, as well as an independent samples t-test, a chi-square test, and a Fisher exact test at P <0.05. The present study findings indicated that 56 (81.2%) out of 76 patients with OCD responded to fluvoxamine treatment. A significant difference between the study groups highlighted age as an influential factor in providing a positive therapeutic response to fluvoxamine (P=0.048). However, the groups did not significantly differ in terms of gender (P=0.272), marital status (P=0.753), educational level (P=0.332), disease duration (P=0.276), and occupational status (P=0.473). While there was no significant difference between the groups (P=0.639) in terms of memory deficits (P=0.639), the response rate to fluvoxamine treatment was significantly higher in those with a healthy executive functioning, compared with patients with impairments in this respect (P=0.043). The obtained data suggested that fluvoxamine has a favorable efficacy in the treatment of OCD, and especially in young patients with healthy executive functioning.
识别治疗反应预测因素有助于改进治疗方案，并根据每个患者的具体情况进行适当调整，从而使患者获得更理想、更快的康复。因此，本研究旨在探讨人口统计学特征、记忆缺陷和执行功能障碍在强迫症（OCD）患者对氟伏沙明治疗无反应中的作用。这项两组设计（治疗反应组和治疗抵抗组）的实验研究对76名接受氟伏沙明单一疗法治疗强迫症≥6个月的参与者进行了探索。研究参与者来自伊朗。本研究使用了四种数据收集工具（即人口统计学数据表、韦氏记忆量表第三版、威斯康星卡片分类测验和耶鲁布朗强迫症量表）。在SPSS - 16中对获得的数据进行描述性统计分析，如均值、标准差、频率和百分比，以及独立样本t检验、卡方检验和Fisher精确检验（P<0.05）。本研究结果表明，76名强迫症患者中有56名（81.2%）对氟伏沙明治疗有反应。研究组之间的显著差异表明年龄是氟伏沙明获得积极治疗反应的一个影响因素（P = 0.048）。然而，两组在性别（P = 0.272）、婚姻状况（P = 0.753）、教育水平（P = 0.332）、病程（P = 0.276）和职业状况（P = 0.473）方面没有显著差异。虽然两组在记忆缺陷方面没有显著差异（P = 0.639），但与执行功能受损的患者相比，执行功能正常的患者对氟伏沙明治疗的反应率显著更高（P = 0.043）。获得的数据表明，氟伏沙明在强迫症治疗中具有良好的疗效，尤其是对执行功能正常的年轻患者。
